Zirconium (89Zr) crefmirlimab berdoxam

This ground-breaking collaboration will enhance accuracy and efficiency of immunotherapy response for improved patient outcomes LOS ANGELES and VALENCIA, Spain, May 2, 2023 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapies (RPT), and Quibim, a global company born with the ambition of transforming imaging data into actionable predictions, are pleased to announce their new collaboration. Together, the two partners aim to revolutionize immunotherapy treatment planning by combining ImaginAb's investigational CD8 ImmunoPET technology with Quibim's cutting-edge image processing technology. Immunotherapy has shown remarkable promise in treating cancer and other diseases, but accurately predicting the efficacy of these treatments remains a challenge. CD8 ImmunoPET™ is an 89Zr-labeled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging. This method is currently being researched to determine whether it may be used to assess the immune status of a patient, to measure the efficacy of immunotherapies, and to predict patient outcomes. As part of this collaboration, Quibim will develop an imaging-based algorithm to interpret CD8 ImmunoPET™ PET/CT exams, with the aim of quantitatively assessing the efficacy of the 89Zr-labeled minibody in targeting the CD8 receptor in the tumor microenvironment. The algorithm will use advanced image processing techniques to extract quantitative measures of tracer uptake in the tumor and surrounding tissues, enabling accurate assessment of the binding efficacy of the minibody to CD8 receptors. The resulting quantitative data will provide valuable insights into the minibody's biodistribution and targeting specificity to inform future clinical development of the imaging agent and its potential therapeutic application. Ian Wilson, Chief Executive Officer of ImaginAb, said: "This partnership presents a unique opportunity to broaden the potential applicability of CD8 ImmunoPET by incorporating advanced image processing techniques into image interpretation. We look forward to working together with Quibim to deepen our understanding of immune imaging with the aim of ultimately improving patient care." Dr. Ángel Alberich, CEO of Quibim, said: "We are thrilled to partner with ImaginAb in this ground-breaking effort to advance in the quantitative assessment of novel radiotracers' efficacy in PET/CT exams. Together, we aim to make a real difference in the lives of patients by improving the accuracy and efficiency of immunotherapy prediction through imaging-based models." Through this collaboration, ImaginAb and Quibim are poised to make significant contributions to the field of immunotherapy with the goal of improving the lives of countless patients. Stay tuned for updates on our progress and breakthroughs. About ImaginAb A clinical stage, revenue-generating global biotechnology company developing next-generation imaging agents and radiopharmaceutical therapy products through its proprietary minibody and cys-diabody platforms. The lead candidate, CD8 ImmunoPET™, is currently in Phase II clinical trials and has been licensed by pharmaceutical and biotech companies for use in immunotherapy clinical trials. For more information, visit About Quibim Quibim, with offices in New York (United States), Cambridge (UK) and Valencia, Madrid and Barcelona (Spain), was born from the ambition of transforming imaging into a catalyst for precision health. This is done designing pioneering tools that unlock imaging data to improve patient outcomes. The company is specialized in the development of AI models created by the use of real-world evidence (RWE) projects and biopharma partners to extract new insights from images; thereby developing novel quantitative imaging biomarkers to deeply analyze disease mechanisms, advance drug development, and monitor treatment progress using a whole-body approach. Quibim leads RWE studies with 10M+ de-identified research imaging registries from 50.000+ oncology patients. For more information, visit SOURCE ImaginAb, Inc.

Leucid Bio will use ImaginAb’s CD8 ImmunoPET tracer along with LEU011 in its basket study to treat solid tumours. Credit: National Cancer Institute on Unsplash. Biotechnology company ImaginAb has entered into a new non-exclusive licence and supply agreement with Leucid Bio for CD8 ImmunoPET technology. ImaginAb will be responsible for licensing and supplying the clinical doses of 89Zr crefmirlimab berdoxam, its investigational CD8 ImmunoPET tracer, to Leucid Bio. Leucid Bio will use the CD8 ImmunoPET tracer along with LEU011 targeting NKG2DL, autologous CAR T-cells, in its basket study to treat solid tumours. ImaginAb CEO Ian Wilson stated: “We are delighted that Leucid Bio will use our investigational CD8 ImmunoPET for the first time in conjunction with CAR-T therapies. “This agreement with Leucid Bio is an opportunity for ImaginAb to continue expanding our partnerships, and showcases the increasing adoption of our CD8 ImmunoPET technology.” CD8 ImmunoPET (89Zr crefmirlimab berdoxam) is an 89Zr-labeled mini body, designed to bind to CD8 receptors on human T cells for non-invasive, quantitative PET imaging. The technique is currently being investigated for diagnosing the immune status of a patient, measuring the efficacy of immunotherapies and predicting patients’ outcomes. Leucid Bio chief business officer Artin Moussavi said: “This is an exciting partnership for Leucid as this cutting-edge technology will provide evidence of the biodistribution of LEU011 CAR T-cells. “This will be the first time this technology will be used in a solid tumour CAR-T clinical setting, allowing Leucid to generate data that demonstrate the tracking of LEU011 to tumour sites in the first phase of the trial. “This data would validate in humans the significant improvements already demonstrated with LEU011 in preclinical studies.” Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.